An ongoing dialogue on HIV/AIDS, infectious diseases,
October 29th, 2011
Will An Antiretroviral Patch Help Adherence? Doubtful …
This little nugget came up recently, found by our Journal Watch Executive Editor:
Preliminary research suggests that a patch could deliver an AIDS drug to patients … The researchers successfully used transdermal patches to administer 96 percent of an AIDS drug to simulated skin over a week. “Still, the important limitation of pills, regardless of how few there are or even how minimal the side effects, is adherence,” Johnston [the investigator] noted. Research has shown that many patients, if not most, don’t take their pills all the time.
Setting aside for a moment the fact that most patients actually do take their medications just fine, thank you — and that this particular transdermal HIV drug delivery system hasn’t even been tested on animals, let alone humans — I have always wondered about the assumption that novel drug delivery systems would improve adherence.
Seems to me that the major problem with non-adherent patients isn’t that they can’t take pills.
It’s that they won’t take them.
And I strongly suspect that most would make the same choice when it comes to putting on a patch every day (or even every week).
Categories: HIV, Patient Care, Research
Tags: antiretroviral therapy, drug delivery systems, HIV
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
2 Responses to “Will An Antiretroviral Patch Help Adherence? Doubtful …”

Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
Search this Blog
Follow HIV and ID Observations Posts via Email
Archives
Most Popular Posts
- When AI Gets the Medical Advice Wrong — and Right
- ID Things to Be Grateful for — 2025 Edition
- What Use Is the Physical Examination in Current Medical Practice?
- Dengue, Malaria, HIV Cure, and Others — First Cold Snap of the Winter ID Link-o-Rama
- SNAP Trial Helps Resolve Long-Running Controversies Over Management of Staph Bacteremia
-
From the Blog — Most Recent Articles
- What Use Is the Physical Examination in Current Medical Practice? December 17, 2025
- Dengue, Malaria, HIV Cure, and Others — First Cold Snap of the Winter ID Link-o-Rama December 10, 2025
- ID Things to Be Grateful for — 2025 Edition November 24, 2025
- When AI Gets the Medical Advice Wrong — and Right November 18, 2025
- Hot Takes from IDWeek: CDC, COVID, and Two Doses of Dalbavancin November 13, 2025
FROM NEJM — Recent Infectious Disease Articles- Interactive Perspective: Measles December 18, 2025This Double Take video reviews evidence-based recommendations on measles prevention and management and explores commonly asked questions about the measles virus and infection.
- Noninferiority of One HPV Vaccine Dose to Two Doses December 18, 2025In this trial, one dose of an HPV vaccine was noninferior to two doses in preventing HPV type 16 or 18 infection.
- From Crisis to Action — Policy Pathways to Reverse the Rise in Congenital Syphilis December 18, 2025In recent years, cases of congenital syphilis have surged. This trend reflects both prenatal care gaps and systemic issues, including failures in testing, treatment, and public health infrastructure.
- Contact Precautions for MRSA and Vancomycin-Resistant Enterococcus December 18, 2025This feature about the use of contact precautions in the hospital for patients with MRSA or VRE offers a case vignette accompanied by two essays, one supporting continuing the use of contact precautions and the other recommending discontinuing them.
- Evidence to Action — Single-Dose HPV Vaccination and Cervical HPV Infection December 18, 2025Kreimer and colleagues now report in the Journal1 the results of the ESCUDDO trial, which showed that the efficacy of a single dose of either a bivalent human papillomavirus (HPV) vaccine or a nonavalent formulation was similar to that of the standard two-dose schedule. This randomized trial...
- Interactive Perspective: Measles December 18, 2025
-
Tag Cloud
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease medical education MRSA PEP PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster

Perhaps most patients in that Baltimore, MD study take their medications just fine… what about those at high risk for nonadherence? Putting on a patch once a week (perhaps supervised during a home visit by a health worker) could be a real improvement over twice-daily pills for some PLH whom I have encountered in a developing country setting. It could certainly be easier for those with a variable sleep or work schedule. I think it would be a simpler option for me if I were on ART.
Hi Amy,
Agree it might be handy … for those who agree to do it!
I also think that Baltimore study is pretty representative of a very challenging group of patients — here’s my review of it:
http://cid.oxfordjournals.org/content/53/6/605.full
My rough estimate is that around 10-20% of HIV patients don’t take their meds, but they loom very large in our minds since we spend so much time agonizing over them!
Paul